Navigation Links
PRoFESS(R) Results Announced at XVII European Stroke Conference
Date:5/14/2008

s of the study. "Landmark trials like PRoFESS will help clinicians make evidence-based treatment choices and ensure that patients receive optimal therapy for their condition."

The other regimen tested in PRoFESS investigated whether Micardis(R) tablets, combined with standard antiplatelet therapy, can further reduce the risk of recurrent stroke. At the end of the study, the results demonstrated that 8.7% of patients experienced recurrent stroke in the MICARDIS arm versus 9.2% in the placebo arm (p=0.23). Thus, the primary endpoint of superiority of MICARDIS versus placebo could not be statistically confirmed. The mean follow-up period was 2.5 years, and it is unclear whether a longer follow-up period would have yielded statistical significance. The PRoFESS results continue to support the safety and tolerability profile of MICARDIS.

"We are proud to have sponsored the PRoFESS study," said Dr. Thor Voigt, Senior Vice President, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We set out to advance the understanding of strategies for recurrent stroke prevention and will continue to evaluate the PRoFESS data to help physicians make more informed treatment decisions."

About PRoFESS(R)

PRoFESS(R) (Prevention Regimen For Effectively avoiding Second Strokes) was designed to examine the effects of different prevention regimens on recurrent stroke, including the antiplatelet agent AGGRENOX versus clopidogrel and the efficacy of MICARDIS, an antihypertensive, compared to placebo in preventing recurrent stroke in the presence of background standard antihypertensive therapy. The trial was a randomized, double-blind, placebo-controlled clinical study that included 20,332 patients from 695 sites in 35 countries, with a four-year follow-up of patients.

PRoFESS is a collaborative effort between academia and the sponsor, Boehringer Ingelheim. Co-funders of the telmisartan arm of the study in selected countries are Ba
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
3. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
4. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
5. DATATRAK International Reports First Quarter Results for 2008
6. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
7. Exelixis Announces First Quarter 2008 Financial Results
8. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
9. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
10. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
11. Senetek PLC Announces Positive Results from Pyratine-6(TM) Clinical Trial in Patients with Acne Rosacea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
(Date:11/21/2014)... , Nov. 21, 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... its previously announced underwritten public offering of $50,000,000 of ... shelf registration statement. The offering will consist of 49,751,244 ... of $1.005 per share.  Lexicon has also granted the ... additional shares of common stock.  All of the shares ...
(Date:11/18/2014)... 18, 2014 Respiratory Motion and IMI Co ... device and services providers in Japan ... Motion,s innovative respiratory depression monitor, the ExSpiron™. As part ... working together to connect the clinical community in promoting ... of bringing innovative medical devices and new technology to ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4
... 14 Merrimack Pharmaceuticals,Inc. today announced that enrollment ... 100 patients that evaluates the safety and efficacy ... rheumatoid arthritis (RA). MM-093 is a,recombinant version of ... Phase 2 study is,being conducted at 20 centers ...
... Inc.,(Amex: ILE ) announced today the completion ... II/III Study IT-A-008 investigating the Isolagen,Therapy(TM) for the ... will be administered at seven clinical sites across ... Isolagen Therapy could hold great promise for the,treatment ...
Cached Medicine Technology:Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 3
(Date:11/23/2014)... November 23, 2014 SWAccessControl.com's high quality ... market. Recently, the company has announced its new collection ... offer on these high quality power suppliers. All the ... off. The special offer lasts until Dec. 20, 2014. ... of them have been supporting it for a long ...
(Date:11/23/2014)... “BlackVue” was featured on NewsWatch as part of ... latest and coolest technology products available to consumers. Mallory ... the product review and shared with viewers how their ... car camera industry. , The need for in-car video ... find the one that’s right per consumer, especially considering ...
(Date:11/23/2014)... 2014 BambooFlooringChina.com , the world’s leader ... strand woven bamboo flooring collection. Now, the business is ... company’s CEO, the promotion is valid until Dec. 20, 2014. ... a smooth and dust-free surface, which makes it very easy ... industry, the company wants to make its website the best ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Cancer researchers ... a connection between intercellular communication tunnels and the growth ... the full story on the Surviving Mesothelioma website. ... and the University of Minnesota have just released their ... information and materials between cells. They found that ...
(Date:11/22/2014)... Recently, Locks-Magnetic.com , one of the successful ... mag locks for glass doors online. In addition, the ... fresh products. Customers can get more information on its ... in excellent performance. Customers who want to buy this ... possible. They also can enjoy the one-stop shopping ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Discounted Mag Locks for Glass Doors Revealed by Locks-Magnetic.com 2
... HealthDay Reporter , THURSDAY, July 29 (HealthDay News) -- ... other when it comes to what patients believe about their ... and what,s the best way to manage the problem, new ... a lack of communication, researchers said. Patients who were "active ...
... cell that has been largely ignored by cancer researchers can, ... by Howard Hughes Medical Institute (HHMI) scientists and their colleagues. ... at the University of California, Los Angeles (UCLA) found that ... the prostate gland. Their studies, which were unveiled in the ...
... Neuroscientists have long wondered how individual connections between brain cells ... in the prestigious science journal Neuron , a new ... of Medicine at Tel Aviv University describes what makes some ... natural molecule that occurs in the brain, which could be ...
... likely the cause of the feminization of fish say researchers ... their study in the journal Environmental Toxicology and Chemistry ... huge geographical area we covered. We found that chemicals ... harm fish were present along approximately 600 km of river," ...
... HealthDay Reporter , THURSDAY, July 29 (HealthDay News) -- Will ... class? Will panels decide what care very sick, older people ... A new Harris Interactive/HealthDay poll shows confusion still reigns when ... President Barack Obama back in March. More than 2,100 ...
... release is available in Spanish . , Mushrooms ... role in keeping the immune system healthy. Now, Agricultural Research ... showing that white button mushrooms enhanced the activity of critical ... States, white button mushrooms represent 90 percent of the total ...
Cached Medicine News:Health News:Doctors, Patients Rarely on Same Page 2Health News:Doctors, Patients Rarely on Same Page 3Health News:A new ground zero for prostate cancer 2Health News:A new ground zero for prostate cancer 3Health News:Memory's master switch 2Health News:Memory's master switch 3Health News:Gender-bending fish on the rise in southern Alberta 2Health News:Americans Still Confused About Health Reform 2Health News:Americans Still Confused About Health Reform 3Health News:Americans Still Confused About Health Reform 4
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Inquire...
... heat-resistant, aluminum foil film designed for the ... minimizes evaportaion and vapor loss during thermal ... devices or mats. Its proprietary adhesive ... Compared to other aluminum foils, AlumaSeal ...
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Medicine Products: